Skip to content

Biomerieux SA Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Fri, Feb 26, 2027, after the market closes · estimates and history

Biomerieux SA · E.BIM.PA · France
Use symbol E.BIM.PA in our API & Excel add-in to retrieve this data ↓
90.40
(0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 75%
Bubble Risk LOW
Realised Volatility (20D) 19.85%

Biomerieux SA Forecast

Biomerieux SA short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 19.9% a year, a typical one-standard-deviation range is 87.87–92.93 over a week, 85.22–95.58 over a month and 72.45–108.35 over a year. (Signals as of 5 Nov 2026.)

Biomerieux SA Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Biomerieux SA
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Biomerieux SA
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Biomerieux SA
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Biomerieux SA
P/E
15.50x
Mid-range vs own history
QoQ +21.3%
YoY −20.1%
now 15.495611.83 low19.81 high
ⓘP/E As of 22 Nov 2026.See Biomerieux SA returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Biomerieux SA
P/S
1.57x
Mid-range vs own history
QoQ +21.3%
YoY −16.6%
now 1.56931.16 low1.94 high
ⓘP/S As of 22 Nov 2026.See Biomerieux SA returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Biomerieux SA
P/B
2.49x
Cheap vs own history
QoQ +21.3%
YoY −23.5%
now 2.49041.9 low3.32 high
ⓘP/B As of 22 Nov 2026.See Biomerieux SA returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Biomerieux SA
EV/EBITDA
6.65x
Mid-range vs own history
QoQ +21.9%
YoY −20.4%
now 6.64794.92 low8.53 high
ⓘEV/EBITDA As of 22 Nov 2026.See Biomerieux SA returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Biomerieux SA
EV/Sales
1.53x
Mid-range vs own history
QoQ +21.9%
YoY −19.2%
now 1.53471.15 low1.94 high
ⓘEV/Sales As of 22 Nov 2026.See Biomerieux SA returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Biomerieux SA
Earnings Yield
6.5%
Mid-range vs own history
QoQ −17.6%
YoY +25.1%
now 6.45345.05 low8.45 high
ⓘEarnings Yield As of 22 Nov 2026.See Biomerieux SA returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Biomerieux SA
Market Cap
$10.7B
Mid-range vs own history
QoQ +21.3%
YoY −16.4%
now 10701.28088,061 low13,433 high
ⓘMarket Cap As of 22 Nov 2026.See Biomerieux SA returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Biomerieux SA
Net Debt
-$236M
Low vs own history
QoQ 0.0%
YoY −287.4%
now -235.9-235.9 low125.9 high
ⓘNet Debt As of 22 Nov 2026.See Biomerieux SA returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Biomerieux SA
Net Debt / EBITDA
-0.15x
Low vs own history
QoQ 0.0%
YoY −284.3%
now -0.1498-0.15 low0.08 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Biomerieux SA returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Biomerieux SA
Current Ratio
2.30x
Mid-range vs own history
QoQ 0.0%
YoY +1.6%
now 2.30152.27 low2.39 high
ⓘCurrent Ratio As of 22 Nov 2026.See Biomerieux SA returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Biomerieux SA
Quick Ratio
1.44x
Mid-range vs own history
QoQ 0.0%
YoY +10.8%
now 1.43661.3 low1.47 high
ⓘQuick Ratio As of 22 Nov 2026.See Biomerieux SA returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Biomerieux SA
Debt / Equity
0.10x
Low vs own history
QoQ 0.0%
YoY −23.7%
now 0.09820.1 low0.13 high
ⓘDebt / Equity As of 22 Nov 2026.See Biomerieux SA returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Biomerieux SA
Altman Z-Score
6.72
Mid-range vs own history
QoQ +13.7%
YoY −11.8%
now 6.71575.51 low7.73 high
ⓘAltman Z-Score As of 22 Nov 2026.See Biomerieux SA returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  14 members-only factors: Revenue Growth, Earnings Growth, EBITDA Growth, Earnings Surprise and moreSign up
Accounting Red Flags
  14 members-only factors: Beneish M-Score, Days Sales in Receivables Index, Gross Margin Index, Asset Quality Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Biomerieux SA, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Biomerieux SA fundamentals: income statement, balance sheet & cash flow

Biomerieux SA reported revenue of €4.07bn and net income of €397.5m in FY2025, the year ended 31 December 2025 — revenue up 2.3% and net income down 8.0% on the prior year. Free cash flow was €453.0m. These figures are as reported in the filings, not restated: 21 fiscal years and 74 quarters of history, back to December 2005.

Revenue (FY2025)
€4.07bn
+2.3%
Net income
€397.5m
-8.0%
Gross margin
52.63%
Free cash flow
€453.0m
+40.9%
Net debt
-€108.4m
Biomerieux SA income statement, annual, as reported · EUR millions unless stated
EUR millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue4,069.83,979.93,674.73,589.13,376.2
Cost of revenue1,927.81,764.61,617.41,628.01,406.8
Gross profit2,142.02,215.32,057.31,961.11,969.4
Research & development507.4491.5460.1446.6385.8
Selling, general & admin.1,073.41,135.01,156.6954.7815.6
Operating income561.2588.8439.1559.8768.0
EBITDA999.6897.5701.3811.9977.8
Interest expense15.816.04.44.19.1
Pre-tax income525.5579.3437.5550.2748.3
Income tax128.8154.3114.5109.7149.4
Net income397.5432.2357.6452.4601.1

Download Biomerieux SA fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BIM.PA&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 21 fiscal years and 74 quarters, the filing vintages behind each number and API access.
Create free account

Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Biomerieux SA

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Biomerieux SA Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Biomerieux SA; 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How Biomerieux SA’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Biomerieux SA behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Biomerieux SA (France)

Biomerieux SA is a listed security in France. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on BIMobject AB

Frequently asked questions

What is Biomerieux SA?
Biomerieux SA is a listed security in France. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Biomerieux SA price?
The latest close is 90.4 (5 Nov 2026), -0.00% on the day. The price at the top of the page refreshes during the trading day.
Is Biomerieux SA in an uptrend?
As of 5 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (7 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Biomerieux SA?
20-day realised volatility is 19.9% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 5.7% over a month and 2.8% over a week.
What factors affect Biomerieux SA?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Biomerieux SA, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Biomerieux SA?
9 backtested tactical asset allocation strategies trade Biomerieux SA through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Biomerieux SA returns analysed?
The Statistical Distribution of Returns section shows the distribution of Biomerieux SA daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Biomerieux SA historical data?
In the Free historical data section of this page: the last 10 years of Biomerieux SA daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Biomerieux SA historical data (last 10 years)

Browse or instantly download the last 10 years of Biomerieux SA daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BIM.PA&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2091.3
2026-11-1991.15
2026-11-1890.75
2026-11-1790.65
2026-11-1691.9
2026-11-1392.8
2026-11-1292.3
2026-11-1192.2
2026-11-1091.65
2026-11-0991.3
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.